Researchers in China have found a gut microbe, Bacteroides vulgatus, that may regulate blood sugar. The microbe and its metabolites can stimulate GLP-1 secretion. GLP-1 is a hormone that controls blood sugar and fullness. The study showed that increasing this microbe in mice can help. This discovery may offer a natural alternative to drugs like … Read more
Between 2018 and 2022, GLP-1 RA use surged among US adults without diabetes, yet adoption remained modest. Medscape Medical News
NAUSEA, constipation, breathing problems, racing heart… the list of Ozempic side effects appears to be growing by the day. And now experts have revealed a new “incredibly common” issue that “nearly everyone” using weight loss injections will experience. instagramCelebrities including Gemma Collins and Rebel Wilson have proudly confessed to using skinny jabs to shed the … Read more
PLAINSBORO, N.J., May 2, 2025 /PRNewswire/ — Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg oral formulation of Wegovy®…
by Daniel J Drucker Nature Reviews Drug Discovery Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025 Apr 25. doi: 10.1038/s41573-025-01183-8. Epub ahead of print. PMID: 40281304. This review article discusses GLP-1-based therapies, highlighting their effectiveness for managing type 2 diabetes and obesity, including well-known drugs like semaglutide and tirzepatide. The text details the evolution … Read more
You may have heard of “Ozempic face” and “Ozempic butt.” Well, now there’s “Ozempic mouth” and “Ozempic feet” to describe more effects of GLP-1 receptor agonists.
New GLP-1 Survey Finds Users Cutting Restaurant Spend Last week’s GLP-1 headlines included Novo Nordisk partnering with telehealth platforms Hims & Hers, LifeMD, and Ro to offer its weight-loss drug Wegovy directly to consumers at substantial discounts, aiming to improve affordability and access. Meanwhile, Eli Lilly reported robust demand for its rival anti-obesity medication, Mounjaro. … Read more
The 50 states ranked by the Obesity Action Coalition (OAC) These sources are a collection of fact sheets from the Obesity Action Coalition (OAC), one for each of the fifty states and the District of Columbia, providing data on the impact of obesity, including state rankings, the percentage of adults classified as obese, overweight, and normal weight, and … Read more
Drugs that both activate and block the GIP receptor reduce weight through different brain mechanisms, offering a new direction for targeted obesity treatments. Drugs that target the receptors for the hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) have proven effective in treating obesity and type 2 diabetes. While GLP-1 and GIP receptor agonists … Read more
May 2, 2025 According to the provided text from Fox News, the World Health Organization (WHO) is planning to endorse the use of GLP-1 weight-loss medications for adults as a strategy to combat the global obesity crisis. This support aims to improve access to these drugs, particularly in low- and middle-income countries, where a significant portion of the world’s obese population resides. The … Read more